Barclays’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.89M | Buy |
1,164,689
+573,683
| +97% | +$2.9M | ﹤0.01% | 1500 |
|
|
2025
Q1 | $3.13M | Sell |
591,006
-42,119
| -7% | -$223K | ﹤0.01% | 1730 |
|
|
2024
Q4 | $4.28M | Sell |
633,125
-64,307
| -9% | -$435K | ﹤0.01% | 1707 |
|
|
2024
Q3 | $4.6M | Buy |
697,432
+304,278
| +77% | +$2.01M | ﹤0.01% | 1590 |
|
|
2024
Q2 | $2.95M | Buy |
393,154
+78,853
| +25% | +$591K | ﹤0.01% | 1449 |
|
|
2024
Q1 | $3.13M | Sell |
314,301
-282,257
| -47% | -$2.81M | ﹤0.01% | 1632 |
|
|
2023
Q4 | $5.88M | Buy |
596,558
+38,787
| +7% | +$383K | ﹤0.01% | 1377 |
|
|
2023
Q3 | $4.27M | Buy |
557,771
+369,103
| +196% | +$2.82M | ﹤0.01% | 1220 |
|
|
2023
Q2 | $1.41M | Buy |
188,668
+446
| +0.2% | +$3.33K | ﹤0.01% | 1951 |
|
|
2023
Q1 | $1.26M | Sell |
188,222
-108,378
| -37% | -$723K | ﹤0.01% | 1976 |
|
|
2022
Q4 | $2.29M | Buy |
296,600
+184,366
| +164% | +$1.42M | ﹤0.01% | 1571 |
|
|
2022
Q3 | $1.2M | Buy |
112,234
+91,762
| +448% | +$977K | ﹤0.01% | 2003 |
|
|
2022
Q2 | $166K | Sell |
20,472
-2,556
| -11% | -$20.7K | ﹤0.01% | 3240 |
|
|
2022
Q1 | $165K | Buy |
+23,028
| New | +$165K | ﹤0.01% | 3429 |
|